CAMBRIDGE, Mass., July 1, 2021 / PRNewswire / – Exacis Biotherapeutics, Inc., a developing immuno-oncology company working to harness the immune system to cure cancer, today announced two significant advances in its manufacturing capabilities. Exacis is partnering with parent company Factor Bioscience to produce its iPSC-derived CAR-T and NK cells in a GMP cleanroom built by Factor, and Exacis has hired Bryan Jones PhD as technical operations manager.
Exacis’ parent company, Factor Bioscience, recently completed construction of a 5,000 square foot GMP cleanroom in its Cambridge, Massachusetts Headquarter. The facility includes two ISO Class 7 clean rooms and is designed to enable the production of advanced mRNA, gene editing and cell therapy products to support all phases of clinical development. Exacis will use this new facility to produce its candidate genetically engineered mRNA cell therapy products for non-clinical and clinical testing.
Exacis’ next-generation approach avoids the use of DNA and viruses and instead uses proprietary and innovative mRNA-based technology. This technology is used to generate iPSCs and to perform gene editing to create potent, targeted allogeneic (ready-to-use) cell therapy products called ExaCAR-T™ and ExaCAR-NK™ cells. The company anticipates that the Factor GMP cleanroom facility will have sufficient capacity to support its programs through advanced clinical development.
Matthew Angel, PhD, CEO of Factor Bioscience, Exacis’ parent company, added, “We have invested in building our GMP cleanroom to give our partners more control over the manufacturing aspects of their cell therapy programs. We look forward to supporting Exacis in its progress. its NK cell and T cell programs through clinical development. “
Bryan jones, PhD, Head of Technical Operations
Dr Jones joins the company with 30 years of drug development experience in a variety of roles, including at the senior management level, allowing him to contribute in many dimensions. Most recently, he was COO at Sollis Therapeutics. Immediately prior to that, he was Vice President of Operations at Sorrento Therapeutics, a leading therapeutic antibody company and one of the early adopters of cell therapy. Dr. Jones will oversee the construction of manufacturing and quality operations in conjunction with Factor Bioscience at the new facility.
“The high cost and long lead times required to manufacture cell therapies are major issues that have hampered progress in the development of new treatments,” said Dr. Jones. “The Exacis technology brings several significant advancements that will enable greater adoption of these highly targeted drugs. “
CEO of Exacis Gregory Fiore MD commented, “We are delighted to announce these major advancements in our ability to maintain control over our own cell supply and quality. Adding Bryan to the head of technical operations and securing a dedicated GMP manufacturing capacity within the Factor factory allows us to produce our unique, high-quality cells on our own schedule as we go. we are moving towards the clinic. “
About Exacis Biotherapeutics
Exacis is a developing immuno-oncology company focused on harnessing the human immune system to cure cancer by designing next-generation, ready-to-use NK and T cell therapies for liquid tumors and solid. Exacis was founded in 2020 with an exclusive license to a wide range of patents covering the use of mRNA-based cell reprogramming and gene editing technologies.
ExaNK™, ExaCAR-NK™ and ExaCAR-T™ use mRNA cell reprogramming and mRNA gene editing technologies developed and owned by Factor Bioscience Exacis holds an exclusive license to Factor Bioscience technology for NK and T cell products derived from iPSC for use in oncology and owns all global development and commercial rights for these experimental candidates.
About Factor Bioscience
Founded in 2011, Factor Bioscience develops cell engineering technologies to advance the study and treatment of disease. Factor Bioscience is a private company headquartered in Cambridge, MA. For more information, visit www.factorbio.com.
About T Cell Therapy and Natural Killer (NK)
T and NK cells are types of human immune cells capable of recognizing and destroying cancer cells and can be genetically engineered to target specific tumors.
View original content: https://www.prnewswire.com/news-releases/exacis-biotherapeutics-makes-strategic-investment-in-manufacturing-by-hiring-head-of-technical-operations-and-securing-space – in-a-gmp-cleanroom-recently-completed-by-bioscience-factor-301324135.html
SOURCE Exacis Biotherapeutics Inc.